Option chain shows key data for PaxMedica's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for PaxMedica.

PaxMedica (OTC:PXMD) Stock, Option Chain

PaxMedica

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

Earnings

News

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Markets

Trading Ideas

LGVN

MRNS

ONVO

PXMD

SNGX

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday.

The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&amp;P 500 also rose, gaining, 0.80% to 5,164.30.

Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings

Small Cap

APLD

EZGO

MOTS

NXPL

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 500 points on Friday.

The Dow traded down 1.37% to 37,934.02 while the NASDAQ fell 1.82% to 16,142.15. The S&amp;P 500 also fell, dropping, 1.61% to 5,115.54.

Nasdaq Down 300 Points; BlackRock Posts Upbeat Earnings

Movers

ADIL

AGEN

ALLR

ANET

BENF

CISS

CMAX

CPNG

DXYZ

FRGE

GATO

GCTS

HRYU

HUBC

INTZ

LOVE

LXEH

LYEL

MGRM

MNDR

MOGU

MRIN

NKLA

NRIX

RENT

RLYB

SAVA

SBFM

SERA

VERU

VIAO

Shares of  JPMorgan Chase &amp; Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

PaxMedica Inc

Guggenheim analyst Joseph Osha reiterates NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Buy and maintains $55 price target.

Price Target

Reiteration

Analyst Ratings

Guggenheim Reiterates Buy on NEXTracker, Maintains $55 Price Target

Truist Securities analyst Jake Bartlett maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Buy and lowers the price target from $70 to $57.

JACK

Truist Securities Maintains Buy on Jack In The Box, Lowers Price Target to $57

Texas Attorney General Ken Paxton has filed a new lawsuit against Dallas, this time targeting Proposition R, a voter-approved amendment decriminalizing possession of up to four ounces of marijuana. The lawsuit marks <a href="https://www.benzinga.com/markets/cannabis/24/01/36880984/gop-attor-ney-gen-er-al-in-texas-sues-five-cities-to-stop-voter-approved-mar-i-jua-na-reform-say">the second time that Paxton has sued the city</a>, intensifying his legal battle against local cannabis reforms.
<h3 class="wp-block-heading">New Cannabis Decriminalization Rules Take Effect in Dallas</h3>
Proposition R, <a href="https://www.benzinga.com/markets/cannabis/24/11/41790734/texas-cannabis-election-dallas-lockhart-bastrop-voters-say-yes-to-marijuana-decriminalization">passed by 66% of Dallas voters on November 5</a>, prohibits police from making arrests or issuing citations for low-level marijuana possession. It also bars officers from using the smell of marijuana as probable cause, unless investigating felonies and mandates that misdemeanor marijuana offenses be a low enforcement priority.&nbsp;
<a href="https://www.dallasnews.com/news/politics/2024/11/21/ag-ken-paxton-sues-dallas-over-decriminalizing-marijuana/">According</a> to The Dallas Morning News, city officials began enforcing the amendment this week, despite warnings of legal challenges.
<h3 class="wp-block-heading">Texas AG Claims Cities Cannot Override State Drug Laws</h3>
Nevertheless, Paxton contends that the amendment violates state law, asserting that cities cannot override Texas drug statutes. &#8220;The city of Dallas has no authority to override Texas drug laws or prohibit the police from enforcing them,&#8221; Paxton <a href="https://texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-city-dallas-ballot-measure-prohibiting-police-enforcing-marijuana">said</a> in a press release on Thursday. 
&#8220;This is a backdoor attempt to violate the Texas Constitution and any city that tries to constrain police in this fashion will be met swiftly with a lawsuit by my office,&#8221; he added.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Paxton Vs. Texas Voter-Backed Cannabis Reforms</h3>
This legal action is part of a broader effort by Paxton to challenge a <a href="https://www.benzinga.com/markets/cannabis/24/11/41764202/dallas-overwhelming-approves-cannabis-decriminalization-in-ballot-vote">statewide trend of voter-led initiatives aimed at decriminalizing cannabis</a>. Earlier this year, <a href="https://www.benzinga.com/markets/cannabis/24/02/37018142/texas-city-slated-to-decriminalize-weed-despite-ag-paxtons-lawsuit-against-five-cities-over-amne">he sued five other cities</a> -Austin, Denton, Elgin, Killeen and San Marcos- over similar measures.&nbsp;
Furthermore, Paxton has repeatedly argued that municipalities lack the authority to override state law, <a href="https://www.benzinga.com/markets/cannabis/24/01/36880984/gop-attor-ney-gen-er-al-in-texas-sues-five-cities-to-stop-voter-approved-mar-i-jua-na-reform-say">calling the actions of these cities</a> "pro-crime extremism."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42069004/how-trumps-election-could-revolutionize-cannabis-and-cryptocurrency-ceo-says">How Trump&#8217;s Election Could Revolutionize Cannabis And Cryptocurrency, CEO Says</a>
Advocacy group Ground Game Texas (GGT), which supported Proposition R, criticized Paxton's lawsuit as baseless. The group argues that the amendment focuses on enforcement priorities rather than legalizing marijuana, making it compliant with state law. Supporters have also highlighted its potential to reduce racial disparities in arrests and prevent the misuse of public funds.
"It's unfortunate but not surprising that Attorney General Ken Paxton has apparently chosen to waste everyone's time and money by filing yet another baseless lawsuit against marijuana decriminalization," said Catina Voellinger, executive director of GGT, according to The Dallas Morning News.
This clash highlights the growing divide between Texas' restrictive cannabis laws and grassroots movements pushing for reform. Judges have previously <a href="https://www.benzinga.com/markets/cannabis/24/07/39946113/gop-attor-ney-gen-er-al-in-texas-loses-legal-battle-against-towns-with-decriminalized-cannabis-i">overturned Paxton's lawsuits against other cities</a>, but appeals remain ongoing.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42127911/gop-led-group-calls-for-legal-cannabis-in-indiana-tell-your-legislator-its-time">GOP-Led Group Calls For Legal Cannabis In Indiana: &#8216;Tell Your Legislator It&#8217;s Time&#8217;</a></li>
</ul>
Image generated with AI tools.

Cannabis

Government

Regulations

Legal

Texas AG Ken Paxton Sues Dallas Over Cannabis Decriminalization Reform

Truist Securities analyst Joel Fishbein maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Buy and raises the price target from $105 to $135.

ESTC

Truist Securities Maintains Buy on Elastic, Raises Price Target to $135

Citigroup analyst Tyler Radke maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $183 to $225.

SNOW

Citigroup Maintains Buy on Snowflake, Raises Price Target to $225

Truist Securities analyst Jamie Cook maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Buy and raises the price target from $496 to $538.

Truist Securities Maintains Buy on Deere, Raises Price Target to $538

Guggenheim analyst Robert Drbul reiterates Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Buy and maintains $35 price target.

Guggenheim Reiterates Buy on Gap, Maintains $35 Price Target

Citigroup analyst Asiya Merchant maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Neutral and raises the price target from $130 to $135.

NTAP

Citigroup Maintains Neutral on NetApp, Raises Price Target to $135

California, known for its ideal climate and rich cannabis history, is regarded as one of the best places to grow weed. The state has also led U.S. cannabis reform, from the first legalization ballot initiative in 1972 to becoming the first state to legalize medical marijuana in 1996. A decade later, in 2016, it legalized recreational use. Since then, California, home to the world's largest cannabis market, has faced significant challenges.
Small pot farms in regions like the Emerald Triangle have struggled to survive due to oversupply and falling prices, <a href="https://www.sfgate.com/cannabis/article/california-cannabis-farms-struggle-19907579.php">writes</a> SF Gate. Issues like <a href="https://anresco.com/exclusive-we-tested-top-california-prerolls-for-potency-inflation/">inappropriate labeling</a>, lab shopping, and a <a href="https://www.benzinga.com/top-stories/24/06/39487551/pesticide-contamination-poses-serious-health-risks-in-californias-cannabis-industry">pesticide scandal</a> have also plagued the industry. While legal cannabis sales <a href="https://www.benzinga.com/markets/cannabis/24/06/39195663/legal-california-cannabis-market-on-the-verge-of-collapse-while-illegal-growers-thrive-destroyin">decline</a>, cartel operations <a href="https://www.benzinga.com/markets/cannabis/24/06/39188435/californias-cartel-cannabis-flourishes-in-national-parks-weed-grown-on-public-lands-accounts-for">thrive in national parks</a>.
To explore these challenges, we spoke to Josh Wurzer, chief compliance officer and co-founder of SC Labs, one of the first to raise concerns about pesticide testing. "From the beginning, our goal has been to be the most science-focused testing laboratory in the cannabis industry," Wurzer told Benzinga.
"We are committed to promoting safe cannabis consumption by ensuring the quality and safety of cannabis cultivation and product manufacturing. Our passion for the plant drives us to support research into its chemical composition, exploring how these compounds influence the flavor, aroma, and unique effects of different strains."
<h2 class="wp-block-heading">Pesticides, Inaccurate Labeling And Lab Shopping</h2>
In 2023, there was a <a href="https://www.benzinga.com/markets/cannabis/24/06/39505507/cannabis-recall-in-california-after-investigation-finds-dangerous-pesticides-in-popular-weed-pro">cannabis recall</a> after an investigation found dangerous pesticides in popular weed products and a lawsuit against <a href="https://www.benzinga.com/markets/cannabis/24/06/39533403/california-lawsuit-takes-aim-at-cannabis-lab-shopping-as-dangerous-pesticides-end-up-in-popular-">cannabis lab shopping</a>. According to Wurzer, who is also a board member of multiple cannabis industry organizations, including the U.S. Pharmacopeial Convention (USP), lab shopping has become a significant issue within the testing industry.
"This problem primarily stems from the fact that the THC concentration in cannabis and cannabis concentrates has become a key factor in determining the wholesale price of these products. This creates a strong incentive for growers and manufacturers to seek out laboratories that report the highest THC concentrations, regardless of the accuracy of the data," he said.
He added that cannabis is vulnerable to pests like spider mites and fungal pathogens like powdery mildew. With no approved pesticides and strict testing requirements, managing these threats is challenging and expensive. Some producers bypass detection by using lenient labs.
While regulators are in charge of overseeing the quality of lab testing, growers and producers are those financially impacted by unfavorable results, Wurzer adds. Without the enforcement of penalties for these actions, "unethical behavior is incentivized."
"I certainly don&#8217;t envy our regulators," he said. "Many of them are working hard to do the best they can within the constraints of the current rules and restrictions. It&#8217;s no small task to try and organize an industry that has been so fragmented, especially when so many people are struggling financially, and there are numerous competing interests at play."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41573828/mold-lead-e-coli-and-other-deadly-contaminants-found-in-90-of-illegal-cannabis-samples-in-uk">Mold, Lead, E.Coli And Other Deadly Contaminants Found In 90% Of Illegal Cannabis Samples In UK</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Cannabis Will Likely Always Be Affected By HLVd</h2>
In 2019, a hop-latent viroid (HLVd) was identified as an infectious pathogen devastating cannabis farms in California by infiltrating plants and ruining entire crops just before they're ready for harvest. According to a 2021 estimate, it affected 90% of California cannabis crops.
Wurzer explained that cannabis will likely always be affected by HLVd, the same way that potato farmers are continuously plagued with the Mosai Virus. However, the cannabis industry has developed a support system that enables growers to mitigate HLVd&#8217;s effects. This has enabled the breeding of resistant strains, improving hygiene practices in nurseries and conducting regular monitoring through testing.
<h2 class="wp-block-heading">Fixing Some Of The Challenges</h2>
In view of HLVd, dangerous pesticides and inaccurate labeling, the question is: have California consumers lost trust in the state&#8217;s legal cannabis products? This could be one of the reasons why the illicit market is still thriving; consumers are turning to cheaper products. Wurzer notes that the price difference between regulated and black markets is significant.
Another challenge comes from the hemp market and the confusion about what is and is not legal. To save the industry, regulators need to address the competition from intoxicating cannabinoids in the hemp market, which is currently mostly unregulated and flooded with dangerous synthetic chemicals, he explains.
Wurzer suggests reducing taxes and regulatory burdens on growers and producers without compromising the quality and safety of products. Profiteers selling unsafe products need to be disincentivized, and ultimately, "the path forward must include federal legalization."
<h2 class="wp-block-heading">Finest Cannabis In The World</h2>
Wurzer believes there's no other place on earth that can match the quality of cannabis grown in California, and "as long as that remains true, we have a real opportunity to fix this mess."
Once cannabis is allowed to cross state lines, California will have a significant advantage, he adds. "No one will want to purchase inferior synthetic THC flowers from other states when they can get high-quality sun-grown flowers from Mendocino, Humboldt, and Santa Cruz. I&#8217;ll confidently put our sun-grown flowers up against the best indoor cannabis produced anywhere else in the world, and I have the lab data to back up those claims."
In April 2023, SC Labs partnered with another major laboratory network to develop the <a href="https://www.benzinga.com/markets/cannabis/23/04/31680816/sc-labs-and-act-laboratories-launch-trust-in-testing-certification-to-set-a-higher-standard-for-">Trust in Testing Certification</a> a set of enhanced national standards for cannabis testing. This program is "designed to address some of the gaps in state regulations that have allowed unscrupulous labs to produce questionable data or manipulate the system," Wurzer details. There's been a significant interest from retailers looking for a trustmark that provides confidence in the products they offer. SC Lab's goal is to establish a group of laboratories dedicated to doing things the right way.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42127449/colorados-marijuana-sales-tax-revenue-slump-amid-hemp-competition">Colorado&#8217;s Marijuana Sales, Tax Revenue Slump Amid Hemp Competition</a></li>
</ul>
Photo: Courtesy of real_content via Shutterstock

Exclusives

Interview

California Has The Finest Weed In The World, Says Lab Expert, And How To Save Its Struggling Market

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here's a look at the Benzinga Stock Whisper Index for the week ending Nov. 22:
Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>): Reader interest in Delta comes after the company <a href="https://www.benzinga.com/24/11/42087211/delta-charts-its-path-to-high-margins-and-shareholder-gains-at-2024-investor-day">hosted an investor day</a> in New York. Among the items shared at the investor day were goals of mid-teen operating margins, 10% average annual EPS growth and $3 billion to $5 billion in annual free cash flow over the next three to five years. 
Delta could also be seeing interest with the new White House administration being ushered in. Delta CEO Ed Bastian <a href="https://www.benzinga.com/news/global/24/11/42106369/delta-chief-says-trump-could-be-a-breath-of-fresh-air-for-aviation-industry">recently said</a> President-elect Donald Trump could provide a "breath of fresh air" for the airline sector after years of "overreach." The Biden administration passed various regulations that protected airline consumers, including automatic refunds after canceled flights and a requirement for airlines to disclose all additional fees and taxes upfront.
Delta also announced it <a href="https://www.benzinga.com/24/11/42095549/delta-will-serve-shake-shack-burgers-as-airline-continues-catering-to-first-class">will start serving</a> Shake Shack burgers to first-class passengers on some flights.
The carrier&#8217;s shares were down over the past week, but remain up over 50% year-to-date. The <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below shows the five-day performance.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="507" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120812/Screenshot-246.png" alt="" class="wp-image-661374" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120812/Screenshot-246.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120812/Screenshot-246-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120812/Screenshot-246-768x391.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>): Bill Ackman's Pershing Square has increased its bet on the apparel company. After <a href="https://www.benzinga.com/news/24/08/40381979/nike-stock-sprints-higher-after-the-bell-as-bill-ackmans-pershing-square-reveals-new-stake">taking a 3 million</a> share stake in the second quarter, a new filing revealed that Ackman added 13 million shares in the third quarter. His firm now owns <a href="https://www.bizjournals.com/portland/news/2024/11/19/nike-bill-ackman-investor-shares-purchased.html">around </a>1.3% of the company. Nike shares trade near 52-week lows after <a href="https://www.benzinga.com/news/earnings/24/10/41129610/nike-q1-earnings-revenue-miss-eps-beat-teams-energized-amid-ceo-transition-a-comeback-at-this-scale">first-quarter financial results</a> saw revenue miss analyst estimates and analysts weigh how quickly a new CEO can help turnaround the company.
"A comeback at this scale takes time, but we see early wins – from momentum in key sports to accelerating our pace of newness and innovation," Nike CFO Matthew Friend said after the Q1 results. "Our teams are energized as Elliott Hill returns to lead Nike's next stage of growth."
Investors could also be closely watching Nike stock to see how <a href="https://www.benzinga.com/markets/asia/24/11/41796941/trump-2-0-a-sneaker-heads-nightmare-your-next-pair-of-nikes-or-vans-could-cost-a-pretty-penny-heres">big of an impact </a>Trump's promise to increase tariffs on other countries could hurt the company.
Nike shares were up slightly on the week and remain down over 27% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120829/Screenshot-247.png" alt="" class="wp-image-661378" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120829/Screenshot-247.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120829/Screenshot-247-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120829/Screenshot-247-768x388.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Autodesk Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>): The software company is seeing strong interest from Benzinga readers ahead of third-quarter financial results scheduled for Tuesday, Nov. 26. Analysts expect the company to report quarterly revenue of $1.56 billion, up from $1.41 billion in last year's third quarter. Analysts also expect quarterly earnings per share of $2.12, up from $2.07 in last year's third quarter. 
Autodesk has beaten analyst estimates for revenue and earnings per share both in five straight quarters. Over the last 10 quarters, Autodesk has beaten analyst estimates for revenue eight times and earnings per share eight times. The company said that it <a href="https://www.benzinga.com/news/earnings/24/08/40639874/autodesk-stock-jumps-5-on-q2-earnings-the-details">was focusing on </a>disciplined execution and seeing GAAP margins among the best in the sector.
Autodesk CEO Andrew Anagnost said these factors &#8220;will deliver sustainable shareholder value over many years.&#8221;
Some <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">recent analyst ratings </a>and price targets are listed below:
<ul>
<li>Wells Fargo: Maintained Overweight rating, raised price target from $340 to $350</li>
<li>Morgan Stanley: Maintained Overweight rating, raised price target from $320 to $375</li>
<li>KeyBanc: Maintained Overweight rating, raised price target from $325 to $330</li>
<li>Scotiabank: Initiated with Sector Outperform rating, $360 price target</li>
<li>Baird: Maintained Outperform rating, raised price target from $305 to $330</li>
<li>Stifel: Maintained Buy rating, raised price target from $320 to $340</li>
<li>Barclays: Maintained Overweight rating, raised price target from $310 to $355</li>
</ul>
Autodesk shares were up 6% over the last five days and are up around 35% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120851/Screenshot-251.png" alt="" class="wp-image-661379" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120851/Screenshot-251.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120851/Screenshot-251-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120851/Screenshot-251-768x389.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): The cryptocurrency company is seeing strong interest as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continues to smash through new all-time highs and near the $100,000 level. 
The rising valuation of other cryptocurrencies could also help offset concerns from Coinbase's recently reported third quarter, which saw revenue and earnings per share miss Street estimates. Trading volume and transaction revenue were down 18% and 27% quarter-over-quarter respectively in <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41637702/coinbase-q3-earnings-highlights-revenue-miss-eps-miss-transaction-revenue-falls-from-q2">the third quarter</a>. 
The <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42131449/with-gary-gensler-preparing-to-quit-in-2025-secs-crypto-cases-likely-to-quietly-go-away-amid-trumps-pro-bitcoin-stance-says-pantera-capitals-katrina-paglia">pro-crypto</a> stance of the incoming Trump administration also boosted interest in cryptocurrency-related companies like Coinbase.
Coinbase stock was up on the week, but trailed the 9.5% gains of Bitcoin. Coinbase stock is up 93.5% year-to-date in 2024, also trailing the year-to-date 122.5% gains for Bitcoin.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120907/Screenshot-252.png" alt="" class="wp-image-661380" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120907/Screenshot-252.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120907/Screenshot-252-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120907/Screenshot-252-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>): The world's largest alternative asset manager <a href="https://www.blackstone.com/news/press/jersey-mikes-to-partner-with-blackstone-to-accelerate-leading-franchisors-continued-growth/">announced </a>plans to acquire a majority stake in Jersey Mike's, a fast-casual restaurant brand. 
While Blackstone won't IPO Jersey Mike's anytime soon. Still, it could benefit from the likelihood that more big IPOs are expected in 2025. 
Reuters reports that medical supply firm Medline, which is partially owned by Blackstone, seeks a $5-billion IPO.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120922/Screenshot-253.png" alt="" class="wp-image-661381" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120922/Screenshot-253.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120922/Screenshot-253-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22120922/Screenshot-253-768x387.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/11/41693907/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">November 1</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42" target="_blank" rel="noreferrer noopener">November 8</a></li>
<li><a href="https://www.benzinga.com/general/space/24/11/42013739/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-43">November 15</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42094292/stock-of-the-day-is-delta-airlines-about-to-takeoff">Stock Of The Day: Delta Air Lines Bullish Pattern Suggests Upside Ahead</a></li>
</ul>

$BTC

ADSK

COIN

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock is trading higher on Friday. On Wednesday the company announced that it submitted <a href="https://www.benzinga.com/24/11/42111748/super-micro-computer-stock-is-rallying-thursday-whats-going-on">a compliance plan to Nasdaq.</a>
The Details: Super Micro, in the compliance plan, said it believes it will be able to file both its 2024 fiscal-year earnings and its 2025 fiscal-year first-quarter earnings within Nasdaq&#8217;s acceptable discretionary time.
Previously, the company reported that it was unable to file its earnings on time for multiple reasons, including the resignation of its previous independent accounting firm, Ernest &amp; Young. The company also explained that its management team needs to time to review the company&#8217;s financial statements and internal controls. 
On Monday the company <a href="https://www.benzinga.com//node/42111748">announced</a> that it has appointed BDO USA as its independent auditor.
"BDO is a highly respected accounting firm with global capabilities.&nbsp;This is an important next step to bring our financial statements current, an effort we are pursuing with both diligence and urgency," said&nbsp;Charles Liang, president and CEO of SuperMicro.
How To Buy Super Micro Computer Stock
By now you're likely curious about how to participate in the market for Super Micro Computer &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Related Link: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42134782/after-plunging-16-microstrategy-makes-modest-recovery-in-friday-pre-market-is-there-still-hope-for-a-100k-btc-effect">After Plunging 16%, MicroStrategy Makes Modest Recovery In Friday Pre-Market: Is There Still Hope For A $100K BTC Effect?</a>
SMCI Price Action: At the time of writing, Super Micro shares are trading 11.2% higher at $33.02, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Shutterstock

SMCI

What's Going On With Super Micro Computer Shares Friday?

Morgan Stanley analyst Stephen Byrd maintains Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Equal-Weight and lowers the price target from $74 to $72.

Morgan Stanley Maintains Equal-Weight on Xcel Energy, Lowers Price Target to $72

Citigroup analyst Tyler Radke maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and raises the price target from $325 to $358.

Citigroup Maintains Buy on Autodesk, Raises Price Target to $358

Morgan Stanley analyst Stephen Byrd maintains Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) with a Overweight and raises the price target from $135 to $169.

Morgan Stanley Maintains Overweight on Vistra, Raises Price Target to $169

Investors with a lot of money to spend have taken a bearish stance on NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVDA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 213 uncommon options trades for NVIDIA.
This isn't normal.
The overall sentiment of these big-money traders is split between 39% bullish and 51%, bearish.
Out of all of the special options we uncovered, 66 are puts, for a total amount of $3,248,837, and 147 are calls, for a total amount of $8,991,099.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $0.5 to $280.0 for NVIDIA over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for NVIDIA options trades today is 21214.15 with a total volume of 3,692,097.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for NVIDIA's big money trades within a strike price range of $0.5 to $280.0 over the last 30 days.
<h3>NVIDIA 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732297547_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/06/24</td>
<td>$2.68</td>
<td>$2.67</td>
<td>$2.67</td>
<td>$147.00</td>
<td>$135.3K</td>
<td>5.0K</td>
<td>3.7K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$2.75</td>
<td>$2.74</td>
<td>$2.75</td>
<td>$143.00</td>
<td>$130.3K</td>
<td>18.5K</td>
<td>16.0K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$3.25</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$142.00</td>
<td>$87.0K</td>
<td>9.6K</td>
<td>5.4K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$150.00</td>
<td>$86.3K</td>
<td>15.7K</td>
<td>3.3K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$0.72</td>
<td>$0.7</td>
<td>$0.7</td>
<td>$150.00</td>
<td>$72.8K</td>
<td>71.2K</td>
<td>51.9K</td>
</tr>
</tbody>
</table>

<h3>About NVIDIA</h3>
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
<h3>NVIDIA's Current Market Status</h3>
<ul>
<li>Trading volume stands at 138,074,002, with NVDA's price down by -3.12%, positioned at $142.1.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 89 days.</li>
</ul>
<h3>Professional Analyst Ratings for NVIDIA</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $177.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Buy, adjusting the price target to $190. 
&#x2A; An analyst from Mizuho persists with their Outperform rating on NVIDIA, maintaining a target price of $175. 
&#x2A; An analyst from Raymond James has decided to maintain their Strong Buy rating on NVIDIA, which currently sits at a price target of $170. 
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on NVIDIA with a target price of $175. 
&#x2A; Reflecting concerns, an analyst from Redburn Atlantic lowers its rating to Buy with a new price target of $178.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest NVIDIA options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

NVDA

Unpacking the Latest Options Trading Trends in NVIDIA

Whales with a lot of money to spend have taken a noticeably bullish stance on Core Scientific.
Looking at options history for Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 64% of the investors opened trades with bullish expectations and 28% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $201,500 and 12, calls, for a total amount of $1,064,776.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $6.0 to $22.0 for Core Scientific over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Core Scientific's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Core Scientific's substantial trades, within a strike price spectrum from $6.0 to $22.0 over the preceding 30 days.
<h3>Core Scientific 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732297541_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$0.55</td>
<td>$0.35</td>
<td>$0.35</td>
<td>$14.50</td>
<td>$175.5K</td>
<td>10</td>
<td>2.3K</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/29/24</td>
<td>$0.35</td>
<td>$0.25</td>
<td>$0.3</td>
<td>$18.50</td>
<td>$149.8K</td>
<td>148</td>
<td>5.0K</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$14.00</td>
<td>$139.7K</td>
<td>26.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$14.00</td>
<td>$129.8K</td>
<td>26.0K</td>
<td>915</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.35</td>
<td>$2.2</td>
<td>$2.35</td>
<td>$20.00</td>
<td>$116.7K</td>
<td>11.6K</td>
<td>528</td>
</tr>
</tbody>
</table>

<h3>About Core Scientific</h3>
Core Scientific Inc is engaged in Blockchain and AI Infrastructure, Digital Asset Self-Mining, Premium Hosting, Blockchain Technology, and Artificial Intelligence related services. The business operates in two segments being; Equipment Sales and Hosting which consists of blockchain infrastructure, third-party hosting business and equipment sales to customers. Mining segment consists of digital asset mining for its account. The blockchain business generates revenue from the sale of consumption-based contracts and by providing hosting services. The digital asset mining segment earns revenue from operating a firm's owned computer equipment as part of a pool of users that process transactions conducted on one or more blockchain networks. In exchange, it receives digital currency assets.
<h3>Present Market Standing of Core Scientific</h3>
<ul>
<li>Trading volume stands at 3,607,522, with CORZ's price down by -0.26%, positioned at $17.5.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 109 days.</li>
</ul>
<h3>Expert Opinions on Core Scientific</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $18.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Core Scientific, targeting a price of $18. 
&#x2A; In a cautious move, an analyst from Jefferies downgraded its rating to Buy, setting a price target of $19. 
&#x2A; Consistent in their evaluation, an analyst from B. Riley Securities keeps a Buy rating on Core Scientific with a target price of $17. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Core Scientific, targeting a price of $17. 
&#x2A; An analyst from BTIG has decided to maintain their Buy rating on Core Scientific, which currently sits at a price target of $19. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Core Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bullish stance on YPF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with YPF, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for YPF.
This isn't normal.
The overall sentiment of these big-money traders is split between 70% bullish and 20%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $132,750, and 9, calls, for a total amount of $350,675.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $43.0 for YPF over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in YPF's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to YPF's substantial trades, within a strike price spectrum from $15.0 to $43.0 over the preceding 30 days.
<h3>YPF Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732297536_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>YPF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.5</td>
<td>$40.00</td>
<td>$132.7K</td>
<td align="right">12</td>
<td align="right">502</td>
</tr>
<tr>
<td>YPF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$27.1</td>
<td>$25.0</td>
<td>$25.0</td>
<td>$15.00</td>
<td>$75.0K</td>
<td align="right">358</td>
<td align="right">30</td>
</tr>
<tr>
<td>YPF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$4.9</td>
<td>$4.7</td>
<td>$4.8</td>
<td>$42.00</td>
<td>$60.4K</td>
<td align="right">134</td>
<td align="right">181</td>
</tr>
<tr>
<td>YPF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$20.5</td>
<td>$18.7</td>
<td>$18.7</td>
<td>$22.00</td>
<td>$37.4K</td>
<td align="right">464</td>
<td align="right">30</td>
</tr>
<tr>
<td>YPF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.25</td>
<td>$1.15</td>
<td>$1.25</td>
<td>$43.00</td>
<td>$33.7K</td>
<td align="right">0</td>
<td align="right">270</td>
</tr>
</tbody>
</table>

<h3>About YPF</h3>
YPF SA is an Argentina-based integrated oil and gas company. It is engaged in operating a fully integrated oil and gas chain across the domestic upstream, downstream, and gas and power segments. The company's upstream operations consist of the exploration, development, and production of crude oil, natural gas, and LPG. Its downstream operations include the refining, marketing, transportation, and distribution of oil and a wide range of petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels. The company generates maximum revenue from the downstream segment.
In light of the recent options history for YPF, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is YPF Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,532,859, the YPF's price is up by 7.77%, now at $40.38. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 11 days.</li>
</ul>
<h3>What Analysts Are Saying About YPF</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $25.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on YPF with a target price of $25. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest YPF options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Looking At YPF's Recent Unusual Options Activity

Donald Trump is back and so is the boom for Palantir (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) – and a couple of its early founders are reaping the benefits. Joe Lonsdale and Stephen Cohen, Peter Thiel&#8217;s close associates, joined the billionaire club thanks to a massive rise in Palantir&#8217;s stock value following Trump's reelection. They own only a small slice of the company – less than 2% each – but it&#8217;s more than enough to make them new billionaires.
Don't Miss:
<ul>
<li>This rooftop wind turbine is taking on a market projected to reach over $900 billion by 2032 —<a href="https://www.benzinga.com/money/halcium"> With already over 40,000 users signing up to purchase, here's a chance to be an early investor today!</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Daddy's home. <a href="https://t.co/0DWZMjlKGx">https://t.co/0DWZMjlKGx</a>
&mdash; Joe Lonsdale (@JTLonsdale) <a href="https://twitter.com/JTLonsdale/status/1855055701980147920?ref_src=twsrc%5Etfw">November 9, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Palantir, the secretive software company known for its work with government agencies, has seen its stock price shoot up more than 270% this year, <a href="https://www.benzinga.com/24/11/42094248/trumps-return-boosts-palantir-national-security-bets-drive-140-billion-market-cap">partly because of Trump's victory</a> and the expectation of increased defense spending. With deep ties to government contracts and projects that align well with Trump's priorities, investors seem to be betting big on Palantir's future.
Joe Lonsdale, who left Palantir in 2009, still holds about a 1% stake in the company, which Forbes estimates is worth roughly $1 billion. Lonsdale, who's been <a href="https://www.benzinga.com/general/politics/24/06/39557155/palantir-co-founders-thiel-lonsdale-back-trump-in-2024-election-id-rather-have-him-than-biden">vocal about his support for Trump's reelection</a>, called this moment &#8220;morning again in America&#8221; and tweeted, &#8220;Daddy&#8217;s Home.&#8221; Through his venture firm 8VC, he's invested in other defense and software companies, solidifying his role as a key figure.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a>
Stephen Cohen, who's still president of Palantir, owns about 1.5% of the company's shares. He and Lonsdale worked closely with Peter Thiel, Palantir's better-known cofounder and were part of Thiel's inner circle during the company&#8217;s early days. Both men – in their early forties – now have significant fortunes due to their involvement in the company, all thanks to their early involvement and the recent surge in its value.
Palantir's recent stock jump hasn't just benefited Lonsdale and Cohen. The two other cofounders, <a href="https://www.benzinga.com/markets/24/11/42028954/peter-thiel-says-trumps-60-china-tariff-would-be-very-very-bad-for-beijing-heres-whats-at-stake">Peter Thiel</a> and <a href="https://www.benzinga.com/news/24/08/40437321/palantirs-alex-karp-defends-military-partnerships-stands-firm-on-pro-western-stance-report">Alex Karp</a>, have been billionaires for quite some time now. The company's valuation <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42039361/palantir-soars-to-150b-market-cap-as-analysts-flag-risks-in-valuation-insider-sales">reached a staggering $150 billion</a> last week, fueled by increased revenues and strong government contracts, including a <a href="https://www.benzinga.com/markets/equities/24/09/40957619/palantir-wins-deal-worth-multi-million-dollars-to-expand-maven-smart-system-across-us-army-air-f">new $99.8 million deal</a> that pushed its quarterly earnings to an all-time high. The fact that Palantir&#8217;s most recent earnings report outperformed analyst estimates has only raised the excitement.
However, the business has its detractors, as some analysts question Palantir&#8217;s exorbitant price. With its market cap now higher than many of its peers in the tech sector and at 55 times its annual revenues, CEO Alex Karp and cofounder Thiel, who have been <a href="https://www.benzinga.com/markets/equities/24/09/41063577/peter-thiel-offloads-over-1b-in-palantir-stock-in-2024-as-stock-more-than-doubles">selling chunks of their stock</a> since Trump's win, haven't exactly calmed these fears. Still, Palantir's unique role as a government contractor and a <a href="https://www.benzinga.com/24/11/41936392/whats-going-on-with-palantir-stock-after-renewing-collaboration-with-rio-tinto">commercial AI leader</a> keeps it in the spotlight.
Read Next:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

PLTR

'Daddy's Home' – Palantir Creates Two New Billionaires After Trump's Win. Both Own Less Than 2% Stock And Are Thiel's Favorites

Jack Mallers, CEO of payment platform Strike, has made a powerful case for the United States to embrace Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42121376/strategic-bitcoin-reserve-wouldnt-require-new-taxpayer-dollars-says-sen-cynthia-lummis">strategic reserve asset</a>.
What Happened: In an <a href="https://x.com/jackmallers/status/1859608923344421177">interview</a> with CNBC on Thursday, Mallers compared the potential adoption of Bitcoin by the U.S. government to pivotal moments in economic history, including Nixon's departure from the gold standard in 1971.
<h3 class="wp-block-heading">A Vision For Bitcoin As A National Asset</h3>
Mallers argued that Bitcoin's decentralized and transparent nature aligns perfectly with American values such as equal rights and open opportunity. 
He described Bitcoin as &#8220;an asset that was accessible to the people 15 years ago, that the people own. Governments only own 2, 3, 4% of this asset.&#8221;
According to Mallers, embracing Bitcoin is a way for the U.S. to remain <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42098407/donald-trump-reportedly-eyeing-the-first-crypto-focused-role-in-the-white-house">competitive and innovative</a>.
"It acts in the best interest of the public. It's pro jobs, it's pro energy, it's pro industry, it's pro growth," he said. 
Highlighting the national debt crisis, Mallers rhetorically asked, &#8220;Does anyone else have a plan to get us out of debt? Are we going to start a lemonade stand out here in Times Square? No. How about the best-performing asset in the history of mankind?&#8221;
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42139601/solana-hits-264-record-high-as-etf-filings-regulatory-optimism-drive-market-momentum">Solana Hits $264 Record High As ETF Filings, Regulatory Optimism Drive Market Momentum</a>
<h3 class="wp-block-heading">Missed Opportunities And Future Growth</h3>
Mallers dismissed the notion that people are &#8220;too late&#8221; to invest in Bitcoin, calling it a distraction rooted in comparison to early adopters. 
"People think they're late to Bitcoin. I don't understand that. Late according to who? Over the last 15 years, the best thing you could have done is buy Bitcoin," he said. 
Mallers went on to assert that this would hold true for the &#8220;next 1,500 years.&#8221;
With the U.S. national debt ballooning and global competitors embracing Bitcoin, Mallers emphasized the urgency of acting now. 
"As a country, I think we have a choice. I think the worst thing we can do is not own enough," he warned. 
He urged the U.S. to support its homegrown crypto businesses, saying, "Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) is an American company, Strike is an American company, Kraken is an American company. Let's support these businesses, let's support this industry."
<h3 class="wp-block-heading">Pro-Growth And Pro-Innovation</h3>
Mallers aligned Bitcoin adoption with the values of the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122348/trumps-planned-crypto-council-may-oversee-bitcoin-reserve-report">incoming U.S. administration</a>, which he sees as an opportunity to drive growth and innovation.
"As this new administration takes office, we have to make a decision. To de-risk this, we should buy some Bitcoin and push American ideals in technology and innovation through the best-performing asset and technology in mankind," he said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138209/microstrategy-trading-at-insane-256-premium-to-bitcoin-holdings-research-shows">MicroStrategy Trading At &#8216;Insane&#8217; 256% Premium To Bitcoin Holdings, Research Shows</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Strike CEO Jack Mallers: 'Bitcoin Is The Best Performing Asset In The History Of Mankind'

Morgan Stanley analyst Stephen Byrd maintains Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) with a Equal-Weight and lowers the price target from $77 to $75.

Morgan Stanley Maintains Equal-Weight on Spire, Lowers Price Target to $75

PaxMedica, Inc. (PXMD) has shared an update. PaxMedica, Inc. has released an updated corporate slide presentation on its website for use in discuss...

PaxMedica Releases Updated Investor Presentation Online

PaxMedica shares soar 125% post-market on drug update

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Friday is here and we&rsquo;re starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!



Moving stocks this morning are earnings reports, stakeholder updates, drug development news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>PaxMedica (NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock is rocketing close to 82% after hitting a <a href="https://www.nasdaq.com/press-release/paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on">key milestone in drug development</a>.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are soaring more than 61% alongside heavy pre-market trading.</li>



<li>Zapata Computing (NASDAQ:<a href="https://investorplace.com/stock-quotes/zpta-stock-quote/">ZPTA</a>) stock is surging over 36% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230226&amp;type=PDF&amp;symbol=ZPTA&amp;cdn=e948601bd73c48c35f25d9d7dd224e92&amp;companyName=Zapata+Computing+Holdings+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-11">following a stakeholder update</a>.</li>



<li>NextPlat (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxpl-stock-quote/">NXPL</a>) shares are rising 32% alongside a <a href="https://www.nasdaq.com/press-release/nextplat-reports-consolidated-year-end-2023-results-with-increased-revenues-of-%2437.8">positive 2023 earnings report</a>.</li>



<li>AMTD Digital (NYSE:<a href="https://investorplace.com/stock-quotes/hkd-stock-quote/">HKD</a>) stock is increasing more than 25% with strong early morning trading.</li>



<li>Beneficient (NASDAQ:<a href="https://investorplace.com/stock-quotes/benf-stock-quote/">BENF</a>) shares are gaining over 25% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230412&amp;type=PDF&amp;symbol=BENF&amp;cdn=eb254668ceab70d3f25ad97304b464e9&amp;companyName=Beneficient&amp;formType=SC+13D%2FA&amp;formDescription=%5BAmend%5D+General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-04-11">a stakeholder update</a>.</li>



<li>NRX Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/nrxp-stock-quote/">NRXP</a>) stock is heading more than 18% higher <a href="https://www.nasdaq.com/press-release/nrxs-nasdaq%3a-nrxp-nmda-modification-therapy-and-its-multiple-applications-from-mental">on therapy news</a>.</li>



<li>Lyell Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/lyel-stock-quote/">LYEL</a>) shares are jumping over 15% this morning.</li>



<li>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) stock is climbing more than 14% on <a href="https://www.nasdaq.com/press-release/fda-grants-soligenix-orphan-drug-designation-for-the-prevention-and-post-exposure">positive drug news</a>.</li>



<li>OncoCyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocx-stock-quote/">OCX</a>) shares are up over 14% with its <a href="https://ng.investing.com/news/stock-market-news/oncocyte-reports-full-year-2023-financial-results-93CH-1298708">Q4 earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Motus GI (NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/">MOTS</a>) stock is plummeting more than 35% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230488&amp;type=PDF&amp;symbol=MOTS&amp;cdn=84b00af3974179838345280e52876622&amp;companyName=Motus+GI+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-11">on a delisting warning</a>.</li>



<li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) shares are diving 17% despite a lack of news today.</li>



<li>Rent the Runway (NASDAQ:<a href="https://investorplace.com/stock-quotes/rent-stock-quote/">RENT</a>) stock is retreating over 15% <a href="https://investorplace.com/2024/04/why-is-rent-the-runway-rent-stock-up-30-today/">after rallying yesterday</a>.</li>



<li>Monogram Orthopaedics (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgrm-stock-quote/">MGRM</a>) shares are tumbling more than 13% as it <a href="https://www.nasdaq.com/press-release/monogram-accepted-to-nvidia-inception-program-2024-04-11">also jumped higher yesterday</a>.</li>



<li>Rallybio (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlyb-stock-quote/">RLYB</a>) stock is pulling back over 11% after a <a href="https://investorplace.com/2024/04/why-is-rallybio-rlyb-stock-up-93-today/">major rally on Thursday</a>.</li>



<li>Applied Digital (NASDAQ:<a href="https://investorplace.com/stock-quotes/apld-stock-quote/">APLD</a>) shares are falling more than 11% with its <a href="https://finance.yahoo.com/news/applied-digital-reports-fiscal-third-200500599.html">fiscal Q3 2024 earnings report</a>.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock is taking an over 10% beating without any clear news this morning.</li>



<li>MOGU (NYSE:<a href="https://investorplace.com/stock-quotes/mogu-stock-quote/">MOGU</a>) shares are decreasing more than 10% with no obvious news to report.</li>



<li>Marin Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrin-stock-quote/">MRIN</a>) stock is dropping over 10% <a href="https://investorplace.com/2024/04/why-is-marin-software-mrin-stock-up-62-today/">after rallying recently</a>.</li>



<li>GCT Semiconductor (NYSE:<a href="https://investorplace.com/stock-quotes/gcts-stock-quote/">GCTS</a>) shares close out our pre-market stock movers down more than 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock is rocketing higher on Friday after the clinical-stage biopharmaceutical company <a href="https://www.nasdaq.com/press-release/paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on">reached a key milestone</a> in drug development.



The big news here is the company securing three pivotal registration/validation batches of PAX-101. The company says that this is a key milestone in its plans for a New Drug Application (NDA) set for Q4 2024.



Investors are celebrating this news as it puts PAX-101 one step closer to approval from the Food and Drug Administration&nbsp;(FDA). If approved, it would be the first first and only form of suramin for the treatment of Stage 1 Human African Trypanosomiasis.



<h2>What&rsquo;s Next for PXMD Stock?</h2>



Howard Weisman, chairman and CEO of&nbsp;PaxMedica, said the following about the company&rsquo;s next plan for PAX-101.




&ldquo;The long-term vision for PaxMedica is to further clinical investigation of PAX-101 as a treatment for individuals who struggle with Autism Spectrum Disorder. With this important manufacturing milestone completed, we have removed a major impediment to testing PAX-101 as a treatment for the core symptoms of Autism Spectrum Disorder.&rdquo;




All of this news brings with it heavy trading of PXMD stock this morning. That has more than 5 million shares changing hands as of this writing. That&rsquo;s quite the leap over its daily average trading volume of about 240,000 shares.



PXMD stock is up 92.7% as of Friday morning.



There are more stock market stories traders need to know about on Friday!



Luckily, we have all of the hottest stock market news ready to go today! That starts with our biggest pre-market stock movers this morning while also catching investors up on yesterday&rsquo;s news. You can dive into all of that at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/04/5-investors-betting-big-on-rent-the-runway-rent-stock/">5 Investors Betting Big on Rent the Runway (RENT) Stock</a></li>



<li><a href="https://investorplace.com/2024/04/cantor-fitzgerald-just-raised-its-rating-on-soundhound-ai-soun-stock/">Cantor Fitzgerald Just Raised Its Rating on SoundHound AI (SOUN) Stock</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is PaxMedica (PXMD) Stock Up 93% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Allarity Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) stock is heading higher on Friday alongside heavy pre-market trading.



Investors will note that this movement comes after the company <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318229974&amp;type=PDF&amp;symbol=ALLR&amp;cdn=994a98b62336e93eb05e904c271966d1&amp;companyName=Allarity+Therapeutics+Inc.&amp;formType=424B5&amp;formDescription=Prospectus+%5BRule+424%28b%29%285%29%5D&amp;dateFiled=2024-04-11">announced a prospectus supplement</a>. This alters the maximum aggregate offering price of shares sold through prospectus from $1,350,000 to $2,350,000.



Allarity Therapeutics notes that it currently has 828,580 shares outstanding with a value of $7,092,593. The amendment mentions that the company has sold $1,348,908 worth of its shares and is eligible to sell $1,015,290 more.



<h2>ALLR Stock Movement Today</h2>



The heavy pre-market trading has more than 2.8 million shares of the clinical-stage biopharmaceutical company&rsquo;s stock changing hands. That&rsquo;s well above its daily average trading volume of about 59,000 shares.



Investors will also note that ALLR stock is up 41.3% as of Friday morning. Even so, the shares closed out Thursday down 78.9% since the start of the year.



Another thing to note is that ALLR is a penny stock. This comes from its low daily average trading volume, prior closing price of $2.30 per share and market capitalization of only $1.0821.082. All of these make it a risky investment.



There are even more of the most recent stock market stories traders will want to read about today below!



We are offering all of the hottest stock market news that investors need to know about on Friday! Among that is what has shares of PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock rising, the biggest pre-market stock movers this morning and more. All of this info is ready to go at the following links!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/04/5-investors-betting-big-on-rent-the-runway-rent-stock/">5 Investors Betting Big on Rent the Runway (RENT) Stock</a></li>
</ul>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Motus GI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/">MOTS</a>) stock is falling on Friday following a warning that the medical technology company is in danger of being delisted.



Motus GI <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230488&amp;type=PDF&amp;symbol=MOTS&amp;cdn=84b00af3974179838345280e52876622&amp;companyName=Motus+GI+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-11">got a delisting notice</a> from the Listing Qualifications Staff of the Nasdaq Exchange on April 5. In that notice, the company was warned about a potential delisting due to its low shares price.



Shares of MOTS stock have been trading for less than $1 each for over 30 business days. That has the company not complying with the minimum bid to remain listed on the exchange.



On that same note, Motus GI has enacted reverse stock splits with a ratio of 250 shares or more to one over the last year. That makes it ineligible for a compliance period to regain the $1 minimum bid.



<h2>What This Means for MOTS Stock</h2>



Motus GI has until today to request a hearing with the Nasdaq Exchange to try and avoid delisting. However, the company doesn&rsquo;t believe it can regain compliance and is choosing not to seek a hearing.



As a result, shares of MOTS stock will stop trading on the Nasdaq Exchange when markets open on Tuesday. This will result in its shares switching over to the OTC Pink Market of the OTCMarkets. It intends to apply for listing on the OTCQB.



Finally, Motus GI says it is exploring a range of strategic options. Its doing so to maximize shareholder value while speeding up the commercialization of its Pure-Vu System.



MOTS stock is down 37.1% as of Friday morning.



There are more stock market stories traders are going to want to read about!



Fortunately, we have a full list of stock market happenings worth reading on Friday! A few examples include what&rsquo;s sending shares of Allarity Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) and PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock higher, as well as the biggest pre-market stock movers this morning. All of that info is available below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-motus-gi-mots-stock-down-37-today/">Why Is Motus GI (MOTS) Stock Down 37% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Motus GI (MOTS) Stock Down 37% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Applied Digital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/apld-stock-quote/">APLD</a>) stock is falling on Friday following the release of the data center company&rsquo;s earnings report for its fiscal third quarter of 2024.



The bad news for APLD stockholders starts with the company&rsquo;s <a href="https://finance.yahoo.com/news/applied-digital-reports-fiscal-third-200500599.html">adjusted earnings per share of -24 cents</a>. That&rsquo;s much worse than the -7 cents per share that Wall Street was expecting. It&rsquo;s also a significant setback compared to the -1 cent per share from the same period of the year prior.



Also not helping matters is Applied Digital&rsquo;s revenue of $43.35 million in fiscal Q3 2024. That&rsquo;s another miss next to analysts&rsquo; revenue estimate of $51.92 million. This is despite it increasing 208% year-over-year from $14.09 million.



Wes Cummins, chairman and CEO of Applied Digital, said this in the earnings report.




&ldquo;During the quarter, Applied Digital encountered several challenges that impacted our financial performance due to facility power outages in our datacenter hosting business. Despite these short-term setbacks, we made significant progress with our key growth initiatives in the development of our Cloud Services business and the establishment of our special purpose built 100 MW HPC datacenter in Ellendale.&rdquo;




<h2>APLD Stock Movement Today</h2>



Investors aren&rsquo;t happy about these latest earnings results from Applied Digital. That has shares of APLD stock falling 5.5% as of Friday morning. That builds on a 55.9% decrease year-to-date as of Thursday&rsquo;s close.



With today&rsquo;s drop in price comes roughly 216,000 shares of APLD stock changing hands. That&rsquo;s well below its daily average trading volume of about 3.5 million shares.



Investors will find even more of the most recent stock market news below!



We have all of the hottest stock market stories worth reading about on Friday! That includes what&rsquo;s going on with shares of Motus GI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/">MOTS</a>) stock, Allarity Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) stock and PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock this morning. All of that info is available at the following links!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-motus-gi-mots-stock-down-37-today/">Why Is Motus GI (MOTS) Stock Down 37% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-applied-digital-apld-stock-down-6-today/">Why Is Applied Digital (APLD) Stock Down 6% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Applied Digital (APLD) Stock Down 6% Today?

DCFC, HUSA and INDO among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
PaxMedica (NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) just reported results for the first quarter of 2024.<ul><li>PaxMedica reported earnings per share of -50 cents. This was below the analyst estimate for EPS of -43 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/pxmd-stock-earnings-paxmedica-for-q1-of-2024/">PXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024

PaxMedica files Nasdaq delisting appeal notice

BROG

DCFC

HGAS

HNRA

HUSA

INDO

KUKE

KZIA

LICY

MDIA

NRXP

SLNH

SPEC

TPET

ZPTA

Health Care

Press Releases

PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

PaxMedica Achieves Key Milestone in the Development of PAX-101  And Provides Update on Potential NDA Submission

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

General

PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast

PaxMedica Provides Company Update and Continues to  Advance PAX-101 Regulatory Strategy

PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101

PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

PaxMedica Secures Immediate Exercise of Warrants

PINKPXMD

HC Wainwright & Co.

Comments

PaxMedica

PaxMedica (PXMD) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga